Matsumae et al. investigated whether cfDNA/ctDNA could serve as predictive markers for treatment outcomes in patients with unresectable hepatocellular carcinoma (u-HCC) receiving anti-PD-L1/VEGF therapy (Atezo/Bev). This evidence concerns the gene CD274 and hepatocellular carcinoma.